FY25 consensus $29.97. In a regulatory filing, the company stated, “Officers of Elevance Health (ELV) expect to speak with investors over the next week. During these meetings, company officers expect to reaffirm the company’s shareholders’ earnings guidance for full year 2025 to be approximately $24.70 per diluted share, including approximately $5.30 per diluted share of net unfavorable items. Excluding these items, the company continues to expect adjusted shareholders’ earnings to be approximately $30.00 per diluted share. This does not include any other adjustment items beyond those reported in the company’s third quarter 2025 earnings. During these meetings, company officers are also expected to reaffirm full year 2025 benefit expense ratio guidance of approximately 90.0%.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Trump Trade: Trump says ‘enrichment’ of health insurers ‘must stop’
- Video: Health insurers weighed on by shutdown news, Trump post
- Trump says ‘enrichment’ of health insurers ‘must stop’
- Elevance Health price target lowered to $400 from $420 at Mizuho
- Enrollees of ACA plans learn of hefty premium increases, WSJ reports
